<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Avelient BioPharm Blog &#187; Social media</title>
	<atom:link href="http://avelient.com/BioPharmBlog/category/advertisingmedia/social-media/feed/" rel="self" type="application/rss+xml" />
	<link>http://avelient.com/BioPharmBlog</link>
	<description>A blog on Biotech, the Pharmaceutical industry, and Personal Health</description>
	<lastBuildDate>Mon, 03 Aug 2009 14:58:06 +0000</lastBuildDate>
	<generator>http://wordpress.org/?v=2.8.2</generator>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
			<item>
		<title>Having the Conversation: How Pharma can Get Social</title>
		<link>http://avelient.com/BioPharmBlog/2009/04/28/having-the-conversation-how-pharma-can-get-social/</link>
		<comments>http://avelient.com/BioPharmBlog/2009/04/28/having-the-conversation-how-pharma-can-get-social/#comments</comments>
		<pubDate>Tue, 28 Apr 2009 10:48:51 +0000</pubDate>
		<dc:creator>Mariano DiFabio</dc:creator>
				<category><![CDATA[Advertising/Media]]></category>
		<category><![CDATA[Economy]]></category>
		<category><![CDATA[Social media]]></category>
		<category><![CDATA[Sociology]]></category>
		<category><![CDATA[Facebook]]></category>
		<category><![CDATA[iAmBiotech]]></category>
		<category><![CDATA[JNJ BTW]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Marc Monseau]]></category>
		<category><![CDATA[Twitter]]></category>
		<category><![CDATA[What Can Biotech do for You?]]></category>

		<guid isPermaLink="false">http://avelient.com/BioPharmBlog/?p=681</guid>
		<description><![CDATA[How can Pharmaceutical companies begin to get social?  They have avoided delving in deeply for some time now, but as social media becomes more prolific, they will be forced to examine their online strategy and possibly forced to adopt some medium that will create a better line of communication with the consumer.  We explore this issue more in this week's post.]]></description>
		<wfw:commentRss>http://avelient.com/BioPharmBlog/2009/04/28/having-the-conversation-how-pharma-can-get-social/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Go Ahead, Pharma: Social Media Okay, says FDA</title>
		<link>http://avelient.com/BioPharmBlog/2009/03/31/go-ahead-pharma-social-media-okay-says-fda/</link>
		<comments>http://avelient.com/BioPharmBlog/2009/03/31/go-ahead-pharma-social-media-okay-says-fda/#comments</comments>
		<pubDate>Tue, 31 Mar 2009 04:01:45 +0000</pubDate>
		<dc:creator>Mariano DiFabio</dc:creator>
				<category><![CDATA[Advertising/Media]]></category>
		<category><![CDATA[Social media]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[pharmacetuical]]></category>

		<guid isPermaLink="false">http://avelient.com/BioPharmBlog/?p=596</guid>
		<description><![CDATA[ 
Big pharmaceuticals have been extraordinarily cautious when it comes to social media as a venue for reaching their customers.  A quick search in Facebook yields groups set up primarily for employees, or fan pages that were set up because somebody was bored at work one day, but nothing of substance that I can point to [...]]]></description>
		<wfw:commentRss>http://avelient.com/BioPharmBlog/2009/03/31/go-ahead-pharma-social-media-okay-says-fda/feed/</wfw:commentRss>
		<slash:comments>2</slash:comments>
		</item>
	</channel>
</rss>
